Phase 3 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who are willing and able to attend all study visits and understand all study-related procedures
- People who have been newly diagnosed with a specific type of ovarian, fallopian tube, or peritoneal cancer (low or high grade serous or endometrioid type, Stage II to IV), confirmed by tissue testing
- People who have undergone surgery to remove as much of the cancer as possible
- People who have a general health and activity level that falls within a certain range (confirm with trial site)
- People who have signed the required consent forms for the study
- People for whom stored tumour tissue samples are available from their diagnosis
- People whose tumour tissue tests positive for a hormone receptor called ER, at a level of at least 1%, as determined by the trial's own testing facility
- People who have completed at least 4 cycles of a platinum-based chemotherapy treatment (including chemotherapy given before surgery)
- Women of childbearing potential who have had, or will have, a surgical procedure or radiation treatment that prevents pregnancy, and who have a negative pregnancy blood test before starting the maintenance treatment phase of the trial
Who may not be able to join:
- People whose cancer continued to grow or spread during their chemotherapy treatment
- Women who are still able to become pregnant and have not had, or will not have, a surgical or radiation procedure to prevent pregnancy before the maintenance treatment phase begins
- People who are currently pregnant or breastfeeding
- People who have had another cancer in the past 5 years that may affect their health outlook
- People who received fewer than 4 cycles of chemotherapy in total
- People for whom hormone-based therapy is medically unsuitable (confirm with trial site)
- People who are unable or unwilling to swallow tablets
- People with a known intolerance to galactose, a condition called lactase deficiency, or a condition called glucose-galactose malabsorption
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Heinzelmann-Schwarz, Prof. MD PhD, University Hospital Basel, Head Women's Hospital
Phone: +41 61 328 42 04
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS) for each study group
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.